| Pharmacogenomics: translating functional genomics into rational therapeutics WE Evans, MV Relling science 286 (5439), 487-491, 1999 | 3362 | 1999 |
| Treatment of acute lymphoblastic leukemia CH Pui, WE Evans New England Journal of Medicine 354 (2), 166-178, 2006 | 2743 | 2006 |
| Pharmacogenomics—drug disposition, drug targets, and side effects WE Evans, HL McLeod New England journal of medicine 348 (6), 538-549, 2003 | 2515 | 2003 |
| Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling EJ Yeoh, ME Ross, SA Shurtleff, WK Williams, D Patel, R Mahfouz, ... Cancer cell 1 (2), 133-143, 2002 | 2419 | 2002 |
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia CG Mullighan, S Goorha, I Radtke, CB Miller, E Coustan-Smith, JD Dalton, ... Nature 446 (7137), 758-764, 2007 | 2174 | 2007 |
| Acute lymphoblastic leukemia CH Pui, MV Relling, JR Downing New England Journal of Medicine 350 (15), 1535-1548, 2004 | 2015 | 2004 |
| The genetic basis of early T-cell precursor acute lymphoblastic leukaemia J Zhang, L Ding, L Holmfeldt, G Wu, SL Heatley, D Payne-Turner, ... Nature 481 (7380), 157-163, 2012 | 1845 | 2012 |
| Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England journal of medicine 371 (11), 1005-1015, 2014 | 1542 | 2014 |
| Treating childhood acute lymphoblastic leukemia without cranial irradiation CH Pui, D Campana, D Pei, WP Bowman, JT Sandlund, SC Kaste, ... New England Journal of Medicine 360 (26), 2730-2741, 2009 | 1454 | 2009 |
| A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study ML Den Boer, M van Slegtenhorst, RX De Menezes, MH Cheok, ... The lancet oncology 10 (2), 125-134, 2009 | 1140 | 2009 |
| Childhood acute lymphoblastic leukemia: progress through collaboration CH Pui, JJ Yang, SP Hunger, R Pieters, M Schrappe, A Biondi, A Vora, ... Journal of Clinical Oncology 33 (27), 2938-2948, 2015 | 1027 | 2015 |
| Moving towards individualized medicine with pharmacogenomics WE Evans, MV Relling Nature 429 (6990), 464-468, 2004 | 1004 | 2004 |
| Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance CR Yates, EY Krynetski, T Loennechen, MY Fessing, HL Tai, CH Pui, ... Annals of internal medicine 126 (8), 608-614, 1997 | 989 | 1997 |
| Pharmacogenomics in the clinic MV Relling, WE Evans Nature 526 (7573), 343-350, 2015 | 912 | 2015 |
| Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. R MV, G EE, S WJ, S K, P CH, Y SW, S CM, C M, E WE, H JK, S M, K TE, ... Clinical Pharmacology & Therapeutics 93 (4), 324-325, 2013 | 894* | 2013 |
| Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. R MV, G EE, S WJ, S K, P CH, Y SW, S CM, C M, E WE, K TE, ... Clinical Pharmacology & Therapeutics 89 (3), 387-391, 2011 | 894 | 2011 |
| Pharmacogenomics and individualized drug therapy M Eichelbaum, M Ingelman-Sundberg, WE Evans Annu. Rev. Med. 57 (1), 119-137, 2006 | 875 | 2006 |
| Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus MV Relling, ML Hancock, GK Rivera, JT Sandlund, RC Ribeiro, ... Journal of the National Cancer Institute 91 (23), 2001-2008, 1999 | 870 | 1999 |
| Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia KG Roberts, RD Morin, J Zhang, M Hirst, Y Zhao, X Su, SC Chen, ... Cancer cell 22 (2), 153-166, 2012 | 865 | 2012 |
| Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia CH Pui, RC Ribeiro, ML Hancock, GK Rivera, WE Evans, SC Raimondi, ... New England Journal of Medicine 325 (24), 1682-1687, 1991 | 857 | 1991 |